Impact of angiotensin converting enzyme inhibitors/angiotensin receptors blockers on mortality in acute heart failure patients with left ventricular systolic dysfunction in the middle east: Observations from the Gulf Acute Heart Failure Registry (Gulf CARE)

Ibrahim Al-Zakwani, Kadhim Sulaiman, Jawad A. Al-Lawati, Alawi A. Alsheikh-Ali, Prashanth Panduranga, Khalid F. Al-Habib, Jassim Al Suwaidi, Wael Al-Mahmeed, Hussam Al-Faleh, Abdelfatah Elasfar, Ahmed Al-Motarreb, Mustafa Ridha, Bassam Bulbanat, Mohammed Al-Jarallah, Nooshin Bazargani, Nidal Asaad, Haitham Amin

Research output: Contribution to journalArticle

Abstract

Aims: To evaluate the impact of Angiotensin-Converting Enzyme Inhibitors (ACEIs)/ Angiotensin Receptors Blockers (ARBs) on in-hospital, 3-and 12-month all-cause mortality in Acute Heart Failure (AHF) patients with left ventricular systolic dysfunction in 7 countries of the Middle East. Methods and Results: Data was analysed from 2,683 consecutive patients admitted with AHF and Left Ventricular Ejection Fraction (LVEF) (<40%) from 47 hospitals from February to November 2012. Analyses were evaluated using univariate and multivariate statistics. The overall mean age of the cohort was 58±15, 72% (n=1,937) were males, 62% (n=1,651) had coronary artery disease, 57% (n=1,539) were hypertensives and 47% (n=1,268) had diabetes. Overall cumulative mortality at inhospital, 3-and 12-month follow-up was 5.8% (n=155), 12.6% (n=338) and 20.4% (n=548), respectively. Adjusting for demographic and clinical characteristics as well as medication in a multivariate logistic regression model, ACEIs were associated with lower risk of in-hospital mortality (adjusted odds ratio (aOR), 0.48; 95% Confidence Interval (CI): 0.25 to 0.94; p=0.031). At 3-month follow-up, both ACEIs (aOR, 0.64; 95% CI: 0.43 to 0.95; p=0.025) and ARBs (aOR, 0.34; 95% CI: 0.18 to 0.62; p<0.001) were associated with lower risk of mortality. Additionally, at 12-month follow-up, those prescribed ACEIs (aOR, 0.71; 95% CI: 0.53 to 0.96; p=0.027) and ARBs (aOR, 0.47; 95% CI: 0.31 to 0.71; p<0.001) were still associated with lower risk of mortality. Conclusion: ACEIs and ARBs treatments were associated with lower mortality risk during admission and up to 12-month of follow-up in Middle East AHF patients with left ventricular systolic dysfunction.

Original languageEnglish
Pages (from-to)596-602
Number of pages7
JournalCurrent Vascular Pharmacology
Volume16
Issue number6
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Middle East
Angiotensin Receptor Antagonists
Left Ventricular Dysfunction
Angiotensin-Converting Enzyme Inhibitors
Registries
Heart Failure
Odds Ratio
Confidence Intervals
Mortality
Hospital Mortality
Logistic Models
Stroke Volume
Coronary Artery Disease
Demography

Keywords

  • Angiotensin receptor antagonists
  • Angiotensin-converting enzyme inhibitors
  • Ejection fraction
  • Heart failure
  • Middle East
  • Mortality

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Impact of angiotensin converting enzyme inhibitors/angiotensin receptors blockers on mortality in acute heart failure patients with left ventricular systolic dysfunction in the middle east : Observations from the Gulf Acute Heart Failure Registry (Gulf CARE). / Al-Zakwani, Ibrahim; Sulaiman, Kadhim; Al-Lawati, Jawad A.; Alsheikh-Ali, Alawi A.; Panduranga, Prashanth; Al-Habib, Khalid F.; Al Suwaidi, Jassim; Al-Mahmeed, Wael; Al-Faleh, Hussam; Elasfar, Abdelfatah; Al-Motarreb, Ahmed; Ridha, Mustafa; Bulbanat, Bassam; Al-Jarallah, Mohammed; Bazargani, Nooshin; Asaad, Nidal; Amin, Haitham.

In: Current Vascular Pharmacology, Vol. 16, No. 6, 01.01.2018, p. 596-602.

Research output: Contribution to journalArticle

Al-Zakwani, I, Sulaiman, K, Al-Lawati, JA, Alsheikh-Ali, AA, Panduranga, P, Al-Habib, KF, Al Suwaidi, J, Al-Mahmeed, W, Al-Faleh, H, Elasfar, A, Al-Motarreb, A, Ridha, M, Bulbanat, B, Al-Jarallah, M, Bazargani, N, Asaad, N & Amin, H 2018, 'Impact of angiotensin converting enzyme inhibitors/angiotensin receptors blockers on mortality in acute heart failure patients with left ventricular systolic dysfunction in the middle east: Observations from the Gulf Acute Heart Failure Registry (Gulf CARE)', Current Vascular Pharmacology, vol. 16, no. 6, pp. 596-602. https://doi.org/10.2174/1570161115666170817164420
Al-Zakwani, Ibrahim ; Sulaiman, Kadhim ; Al-Lawati, Jawad A. ; Alsheikh-Ali, Alawi A. ; Panduranga, Prashanth ; Al-Habib, Khalid F. ; Al Suwaidi, Jassim ; Al-Mahmeed, Wael ; Al-Faleh, Hussam ; Elasfar, Abdelfatah ; Al-Motarreb, Ahmed ; Ridha, Mustafa ; Bulbanat, Bassam ; Al-Jarallah, Mohammed ; Bazargani, Nooshin ; Asaad, Nidal ; Amin, Haitham. / Impact of angiotensin converting enzyme inhibitors/angiotensin receptors blockers on mortality in acute heart failure patients with left ventricular systolic dysfunction in the middle east : Observations from the Gulf Acute Heart Failure Registry (Gulf CARE). In: Current Vascular Pharmacology. 2018 ; Vol. 16, No. 6. pp. 596-602.
@article{43ce412713534962b7af3f040c0189a9,
title = "Impact of angiotensin converting enzyme inhibitors/angiotensin receptors blockers on mortality in acute heart failure patients with left ventricular systolic dysfunction in the middle east: Observations from the Gulf Acute Heart Failure Registry (Gulf CARE)",
abstract = "Aims: To evaluate the impact of Angiotensin-Converting Enzyme Inhibitors (ACEIs)/ Angiotensin Receptors Blockers (ARBs) on in-hospital, 3-and 12-month all-cause mortality in Acute Heart Failure (AHF) patients with left ventricular systolic dysfunction in 7 countries of the Middle East. Methods and Results: Data was analysed from 2,683 consecutive patients admitted with AHF and Left Ventricular Ejection Fraction (LVEF) (<40{\%}) from 47 hospitals from February to November 2012. Analyses were evaluated using univariate and multivariate statistics. The overall mean age of the cohort was 58±15, 72{\%} (n=1,937) were males, 62{\%} (n=1,651) had coronary artery disease, 57{\%} (n=1,539) were hypertensives and 47{\%} (n=1,268) had diabetes. Overall cumulative mortality at inhospital, 3-and 12-month follow-up was 5.8{\%} (n=155), 12.6{\%} (n=338) and 20.4{\%} (n=548), respectively. Adjusting for demographic and clinical characteristics as well as medication in a multivariate logistic regression model, ACEIs were associated with lower risk of in-hospital mortality (adjusted odds ratio (aOR), 0.48; 95{\%} Confidence Interval (CI): 0.25 to 0.94; p=0.031). At 3-month follow-up, both ACEIs (aOR, 0.64; 95{\%} CI: 0.43 to 0.95; p=0.025) and ARBs (aOR, 0.34; 95{\%} CI: 0.18 to 0.62; p<0.001) were associated with lower risk of mortality. Additionally, at 12-month follow-up, those prescribed ACEIs (aOR, 0.71; 95{\%} CI: 0.53 to 0.96; p=0.027) and ARBs (aOR, 0.47; 95{\%} CI: 0.31 to 0.71; p<0.001) were still associated with lower risk of mortality. Conclusion: ACEIs and ARBs treatments were associated with lower mortality risk during admission and up to 12-month of follow-up in Middle East AHF patients with left ventricular systolic dysfunction.",
keywords = "Angiotensin receptor antagonists, Angiotensin-converting enzyme inhibitors, Ejection fraction, Heart failure, Middle East, Mortality",
author = "Ibrahim Al-Zakwani and Kadhim Sulaiman and Al-Lawati, {Jawad A.} and Alsheikh-Ali, {Alawi A.} and Prashanth Panduranga and Al-Habib, {Khalid F.} and {Al Suwaidi}, Jassim and Wael Al-Mahmeed and Hussam Al-Faleh and Abdelfatah Elasfar and Ahmed Al-Motarreb and Mustafa Ridha and Bassam Bulbanat and Mohammed Al-Jarallah and Nooshin Bazargani and Nidal Asaad and Haitham Amin",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1570161115666170817164420",
language = "English",
volume = "16",
pages = "596--602",
journal = "Current Vascular Pharmacology",
issn = "1570-1611",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - Impact of angiotensin converting enzyme inhibitors/angiotensin receptors blockers on mortality in acute heart failure patients with left ventricular systolic dysfunction in the middle east

T2 - Observations from the Gulf Acute Heart Failure Registry (Gulf CARE)

AU - Al-Zakwani, Ibrahim

AU - Sulaiman, Kadhim

AU - Al-Lawati, Jawad A.

AU - Alsheikh-Ali, Alawi A.

AU - Panduranga, Prashanth

AU - Al-Habib, Khalid F.

AU - Al Suwaidi, Jassim

AU - Al-Mahmeed, Wael

AU - Al-Faleh, Hussam

AU - Elasfar, Abdelfatah

AU - Al-Motarreb, Ahmed

AU - Ridha, Mustafa

AU - Bulbanat, Bassam

AU - Al-Jarallah, Mohammed

AU - Bazargani, Nooshin

AU - Asaad, Nidal

AU - Amin, Haitham

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Aims: To evaluate the impact of Angiotensin-Converting Enzyme Inhibitors (ACEIs)/ Angiotensin Receptors Blockers (ARBs) on in-hospital, 3-and 12-month all-cause mortality in Acute Heart Failure (AHF) patients with left ventricular systolic dysfunction in 7 countries of the Middle East. Methods and Results: Data was analysed from 2,683 consecutive patients admitted with AHF and Left Ventricular Ejection Fraction (LVEF) (<40%) from 47 hospitals from February to November 2012. Analyses were evaluated using univariate and multivariate statistics. The overall mean age of the cohort was 58±15, 72% (n=1,937) were males, 62% (n=1,651) had coronary artery disease, 57% (n=1,539) were hypertensives and 47% (n=1,268) had diabetes. Overall cumulative mortality at inhospital, 3-and 12-month follow-up was 5.8% (n=155), 12.6% (n=338) and 20.4% (n=548), respectively. Adjusting for demographic and clinical characteristics as well as medication in a multivariate logistic regression model, ACEIs were associated with lower risk of in-hospital mortality (adjusted odds ratio (aOR), 0.48; 95% Confidence Interval (CI): 0.25 to 0.94; p=0.031). At 3-month follow-up, both ACEIs (aOR, 0.64; 95% CI: 0.43 to 0.95; p=0.025) and ARBs (aOR, 0.34; 95% CI: 0.18 to 0.62; p<0.001) were associated with lower risk of mortality. Additionally, at 12-month follow-up, those prescribed ACEIs (aOR, 0.71; 95% CI: 0.53 to 0.96; p=0.027) and ARBs (aOR, 0.47; 95% CI: 0.31 to 0.71; p<0.001) were still associated with lower risk of mortality. Conclusion: ACEIs and ARBs treatments were associated with lower mortality risk during admission and up to 12-month of follow-up in Middle East AHF patients with left ventricular systolic dysfunction.

AB - Aims: To evaluate the impact of Angiotensin-Converting Enzyme Inhibitors (ACEIs)/ Angiotensin Receptors Blockers (ARBs) on in-hospital, 3-and 12-month all-cause mortality in Acute Heart Failure (AHF) patients with left ventricular systolic dysfunction in 7 countries of the Middle East. Methods and Results: Data was analysed from 2,683 consecutive patients admitted with AHF and Left Ventricular Ejection Fraction (LVEF) (<40%) from 47 hospitals from February to November 2012. Analyses were evaluated using univariate and multivariate statistics. The overall mean age of the cohort was 58±15, 72% (n=1,937) were males, 62% (n=1,651) had coronary artery disease, 57% (n=1,539) were hypertensives and 47% (n=1,268) had diabetes. Overall cumulative mortality at inhospital, 3-and 12-month follow-up was 5.8% (n=155), 12.6% (n=338) and 20.4% (n=548), respectively. Adjusting for demographic and clinical characteristics as well as medication in a multivariate logistic regression model, ACEIs were associated with lower risk of in-hospital mortality (adjusted odds ratio (aOR), 0.48; 95% Confidence Interval (CI): 0.25 to 0.94; p=0.031). At 3-month follow-up, both ACEIs (aOR, 0.64; 95% CI: 0.43 to 0.95; p=0.025) and ARBs (aOR, 0.34; 95% CI: 0.18 to 0.62; p<0.001) were associated with lower risk of mortality. Additionally, at 12-month follow-up, those prescribed ACEIs (aOR, 0.71; 95% CI: 0.53 to 0.96; p=0.027) and ARBs (aOR, 0.47; 95% CI: 0.31 to 0.71; p<0.001) were still associated with lower risk of mortality. Conclusion: ACEIs and ARBs treatments were associated with lower mortality risk during admission and up to 12-month of follow-up in Middle East AHF patients with left ventricular systolic dysfunction.

KW - Angiotensin receptor antagonists

KW - Angiotensin-converting enzyme inhibitors

KW - Ejection fraction

KW - Heart failure

KW - Middle East

KW - Mortality

UR - http://www.scopus.com/inward/record.url?scp=85053802478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053802478&partnerID=8YFLogxK

U2 - 10.2174/1570161115666170817164420

DO - 10.2174/1570161115666170817164420

M3 - Article

AN - SCOPUS:85053802478

VL - 16

SP - 596

EP - 602

JO - Current Vascular Pharmacology

JF - Current Vascular Pharmacology

SN - 1570-1611

IS - 6

ER -